The Ohio State University was awarded a multi-PI (MPI) Program Grant P01 entitled “Role of the non-canonical inflammasome in SARS-CoV-2-mediated pathology and coagulopathy”. Drs. Amal Amer (contact), Estelle Cormet-Boyaka, and Jianrong Li are the PIs on this five-year, $15M award.

Dr. Amal Amer (center) leads a group of scientists studying long COVID. With her are (from left): 
Drs. Santiago Partida-Sanchez, Jianrong Li, Maciej Pietrzak, Yacob Yount, Xiaoli Zhang, Prosper Boyaka, and Estelle Cormet-Boyaka.

The PO1 program structure is as follows:
 

• Project 1: Role of CASP-11 in SARS-CoV-2- induced lung pathologies and long-term immune protection (Project Leader: Prosper Boyaka; Co-Investigators: Estelle Cormet-Boyaka, Jacob Yount)
• Project 2: CASP-11-dependent immunothrombosis and neuroinflammation during SARS-CoV2 infection (Project Leader: Amal Amer; Co-Investigators: Stephanie Seveau, Andrea Tedeschi, Amy Webb)
• Project 3:   CASP-11-dependent RNA modifications and their Role in Multi-Organ Pathologies (Project Leader: Jianrong Li; Co-Investigators: Mark Peeples, Chuan He)
• Administrative Core (Core Leader: Amal Amer; Co-Investigators: Estelle Cormet-Boyaka, Jianrong Li)
• Biostatistics and Bioinformatics Core (Core Leader: Xiaoli Zhang; Co-Investigators: Maciej Pietrzak)
• Biological Reagents and Infection Core (Core Leader: Jianrong Li; Co-Investigator: Mark Peeples)
• Cell Derivation and Maintenance Core (Core Leader: Estelle Cormet-Boyaka; Co-Investigator: Santiago Partida-Sanchez)